BriaCell Reports Volatile Q4 Results, Eyes Breakthrough with BriaVax
BriaCell Therapeutics shares volatile 2025 results, with its BriaVax breast‑cancer vaccine driving investor interest and a negative P/E yet strong market cap.
2 minutes to read
BriaCell Therapeutics Corp
BriaCell’s BriaVax Breakthrough Sparks Volatile Stock Surge — What It Means for Investors
BriaCell Therapeutics Corp’s latest quarterly results reveal sharp stock swings yet steady progress on its BriaVax breast‑cancer vaccine, underscoring biotech’s high‑risk, high‑reward journey toward breakthrough immunotherapies.
2 minutes to read
BriaCell Shows Phase 2 Survival Wins, Phase 3 Enrollment On Track
BriaCell’s whole‑cell breast‑cancer vaccine, Bria‑IMT, shows significant overall‑survival gains in Phase 2 and hits Phase 3 enrollment milestones, positioning the company for potential accelerated approval and market launch.
3 minutes to read